{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:34:42Z","timestamp":1794854082141,"version":"4.9.1"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019125","name":"National Institute of Pharmaceutical Education and Research, Ahmedabad","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019125","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Colloids and Surfaces B: Biointerfaces"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.colsurfb.2025.115034","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T15:23:17Z","timestamp":1755012197000},"page":"115034","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"P2","title":["Enhancing oral bioavailability of pazopanib via co-amorphous system: Formulation, characterization, pharmacokinetics and toxicity evaluation"],"prefix":"10.1016","volume":"256","author":[{"given":"Khushi","family":"Rode","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indrani","family":"Maji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anish","family":"Dhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharath","family":"Manoharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanmoy","family":"Kanp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezhilmathe","family":"Athavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Munagalasetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hara Prasad","family":"Padhy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandraiah","family":"Godugu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasundhra","family":"Bhandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8462-2170","authenticated-orcid":false,"given":"Pankaj Kumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.colsurfb.2025.115034_bib1","doi-asserted-by":"crossref","DOI":"10.1142\/S225123732440015X","article-title":"A comprehensive literature review on efficient synthetic approaches and polymorphism of pazopanib (Votrient), a tyrosine kinase inhibitor","volume":"12","author":"Chand","year":"2024","journal-title":"J. Mol. Eng. Mater."},{"key":"10.1016\/j.colsurfb.2025.115034_bib2","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.biopha.2017.10.058","article-title":"The role of pazopanib on tumour angiogenesis and in the management of cancers: a review","volume":"96","author":"Chellappan","year":"2017","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.colsurfb.2025.115034_bib3","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ijpharm.2018.04.037","article-title":"Solubility and bioavailability improvement of pazopanib hydrochloride","volume":"544","author":"Herbrink","year":"2018","journal-title":"Int. J. Pharm."},{"issue":"9","key":"10.1016\/j.colsurfb.2025.115034_bib4","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.3390\/pharmaceutics14091875","article-title":"Preparation and characterization of pazopanib Hydrochloride-Loaded Four-Component Self-Nanoemulsifying drug delivery systems preconcentrate for enhanced solubility and dissolution","volume":"14","author":"Choi","year":"2022","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.colsurfb.2025.115034_bib5","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1080\/00498254.2018.1489167","article-title":"A metabolomic perspective of pazopanib-induced acute hepatotoxicity in mice","volume":"49","author":"Wang","year":"2019","journal-title":"Xenobiotica"},{"issue":"2","key":"10.1016\/j.colsurfb.2025.115034_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103863","article-title":"Recent advances in dual-drug co-amorphous systems","volume":"29","author":"Shelke","year":"2024","journal-title":"Drug Discov. Today"},{"issue":"3","key":"10.1016\/j.colsurfb.2025.115034_bib7","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3390\/pharmaceutics13030389","article-title":"Co-amorphous drug formulations in numbers: recent advances in co-amorphous drug formulations with focus on co-formability, molar ratio, preparation methods, physical stability, in vitro and in vivo performance, and new formulation strategies","volume":"13","author":"Liu","year":"2021","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.colsurfb.2025.115034_bib8","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1021\/acs.molpharmaceut.9b00105","article-title":"Application of co-amorphous technology for improving the physicochemical properties of amorphous formulations","volume":"16","author":"Mizoguchi","year":"2019","journal-title":"Mol. Pharm."},{"issue":"15","key":"10.1016\/j.colsurfb.2025.115034_bib9","doi-asserted-by":"crossref","first-page":"5623","DOI":"10.3390\/molecules28155623","article-title":"Phytochemical properties, extraction, and pharmacological benefits of naringin: a review","volume":"28","author":"Shilpa","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.colsurfb.2025.115034_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104050","article-title":"Unlocking the potential of flavonoid-based cocrystal and co-amorphous systems","author":"Rode","year":"2024","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.colsurfb.2025.115034_bib11","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.phymed.2018.03.051","article-title":"Anti-inflammatory and antioxidant activities of naringin isolated from carissa carandas L.: in vitro and in vivo evidence","volume":"42","author":"El-Desoky","year":"2018","journal-title":"Phytomedicine"},{"key":"10.1016\/j.colsurfb.2025.115034_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105264","article-title":"Naringin and naringenin as anticancer agents and adjuvants in cancer combination therapy: efficacy and molecular mechanisms of action, a comprehensive narrative review","volume":"171","author":"Memariani","year":"2021","journal-title":"Pharmacol. Res."},{"issue":"2","key":"10.1016\/j.colsurfb.2025.115034_bib13","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/01480545.2020.1719132","article-title":"Naringenin: a potential natural remedy against methotrexate-induced hepatotoxicity in rats","volume":"45","author":"Malayeri","year":"2022","journal-title":"Drug Chem. Toxicol."},{"issue":"8","key":"10.1016\/j.colsurfb.2025.115034_bib14","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1002\/ptr.6641","article-title":"Protective effects of naringin against drugs and chemical toxins induced hepatotoxicity: a review","volume":"34","author":"Shirani","year":"2020","journal-title":"Phytother. Res."},{"issue":"2","key":"10.1016\/j.colsurfb.2025.115034_bib15","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/15376516.2019.1669243","article-title":"Zinc abrogates anticancer drug tamoxifen-induced hepatotoxicity by suppressing redox imbalance, NO\/iNOS\/NF-\u0138B signaling, and caspase-3-dependent apoptosis in female rats","volume":"30","author":"Famurewa","year":"2020","journal-title":"Toxicol. Mech. Methods"},{"key":"10.1016\/j.colsurfb.2025.115034_bib16","author":"Khaled","year":"2023","journal-title":"Nar. Nar. Count. taxolInduc. hepatic liver Inj. Wistar Rats. via Suppr. Oxid. Stress apoptosis Inflamm."},{"key":"10.1016\/j.colsurfb.2025.115034_bib17","article-title":"Strategy to counteract the pyrazinamide induced hepatotoxicity by developing naringin based co-amorphous system with supplementary benefits","volume":"69","author":"Prajapati","year":"2022","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"2","key":"10.1016\/j.colsurfb.2025.115034_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.103883","article-title":"Drug\u2013drug co-amorphous systems: an emerging formulation strategy for poorly water-soluble drugs","volume":"29","author":"Wang","year":"2024","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.colsurfb.2025.115034_bib19","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s12247-019-09381-9","article-title":"Influence of preparation methods on physicochemical and pharmacokinetic properties of co-amorphous formulations: the case of co-amorphous atorvastatin: naringin","volume":"15","author":"Nair","year":"2020","journal-title":"J. Pharm. Innov."},{"key":"10.1016\/j.colsurfb.2025.115034_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116527","article-title":"A new framework for novel analogues of pazopanib as potent and selective human carbonic anhydrase inhibitors: design, repurposing rational, synthesis, crystallographic, in vivo and in vitro biological assessments","author":"Hefny","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.colsurfb.2025.115034_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.123784","article-title":"Dasatinib loaded mucoadhesive lecithin-chitosan hybrid nanoparticles for its augmented oral delivery, in-vitro efficacy and safety","volume":"651","author":"Mehandole","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.colsurfb.2025.115034_bib22","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.carbpol.2017.10.030","article-title":"1, 3\u03b2-Glucan anchored, paclitaxel loaded chitosan nanocarrier endows enhanced hemocompatibility with efficient anti-glioblastoma stem cells therapy","volume":"180","author":"Singh","year":"2018","journal-title":"Carbohydr. Polym."},{"issue":"3","key":"10.1016\/j.colsurfb.2025.115034_bib23","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1021\/acs.molpharmaceut.3c00947","article-title":"Preparation and characterization of a rifampicin coamorphous material with tromethamine coformer: an Experimental\u2013Theoretical study","volume":"21","author":"Queiroz","year":"2024","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.colsurfb.2025.115034_bib24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejpb.2020.03.002","article-title":"Detection of amorphous-amorphous phase separation in small molecular co-amorphous mixtures with SEM-EDS","volume":"150","author":"Pajula","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.colsurfb.2025.115034_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120389","article-title":"Sinomenine-phenolic acid coamorphous drug systems: solubilization, sustained release, and improved physical stability","volume":"598","author":"Chen","year":"2021","journal-title":"Int. J. Pharm."},{"issue":"5","key":"10.1016\/j.colsurfb.2025.115034_bib26","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s12161-024-02606-9","article-title":"A novel Stability-Indicating RP-HPLC method for the simultaneous estimation and in vitro and in vivo evaluation: curcumin and naringin Co-amorphous system","volume":"17","author":"Mallya","year":"2024","journal-title":"Food Anal. Methods"},{"key":"10.1016\/j.colsurfb.2025.115034_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.molliq.2024.124458","article-title":"Fabrication of \u03b2-cyclodextrin and 2-hydroxypropyl-\u03b2-cyclodextrin inclusion complexes of palbociclib: physicochemical characterization, solubility enhancement, in-silico studies, in vitro assessment in MDA-MB-231 cell line","volume":"399","author":"Paul","year":"2024","journal-title":"J. Mol. Liq."},{"key":"10.1016\/j.colsurfb.2025.115034_bib28","article-title":"Development and validation of stability indicating method for the estimation of pazopanib hydrochloride in pharmaceutical dosage forms by RP-HPLC","author":"Ashok","year":"2018","journal-title":"GORJA ASHOK (Reg. No. 1268114209)"},{"key":"10.1016\/j.colsurfb.2025.115034_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ces.2023.118618","article-title":"Prediction of co-amorphous formation using non-bonded interaction energy: molecular dynamic simulation and experimental validation","volume":"272","author":"Deng","year":"2023","journal-title":"Chem. Eng. Sci."},{"issue":"5","key":"10.1016\/j.colsurfb.2025.115034_bib30","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ejmech.2006.01.013","article-title":"Prediction of human absorption of natural compounds by the non-everted rat intestinal sac model","volume":"41","author":"Ruan","year":"2006","journal-title":"Eur. J. Med. Chem."},{"issue":"10","key":"10.1016\/j.colsurfb.2025.115034_bib31","first-page":"1113","article-title":"Combinatorial delivery of ribociclib and Green tea extract mediated nanostructured lipid carrier for oral delivery for the treatment of breast cancer synchronising in silico, in vitro, and in vivo studies","volume":"30","author":"Sartaj","year":"2022","journal-title":"J. Drug Target."},{"issue":"3","key":"10.1016\/j.colsurfb.2025.115034_bib32","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in microsoft excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput. Methods Prog. Biomed."},{"key":"10.1016\/j.colsurfb.2025.115034_bib33","unstructured":"J. Li, A Berberine Hydrochloride-Chlorogenic Acid Coamorphous System with Gastric Ulcer Protection and Bacteriostatic Effects: Preparation, Characterization and in Vitro Performance Evaluation. Characterization and in Vitro Performance Evaluation.."},{"key":"10.1016\/j.colsurfb.2025.115034_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122287","article-title":"Pazopanib-laden lipid based nanovesicular delivery with augmented oral bioavailability and therapeutic efficacy against non-small cell lung cancer","volume":"628","author":"Nadaf","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.colsurfb.2025.115034_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.poly.2020.114694","article-title":"Synthesis and characterization of a novel soluble neohesperidin-copper (II) complex using Ion-exchange resin column","volume":"188","author":"Xia","year":"2020","journal-title":"Polyhedron"},{"issue":"39","key":"10.1016\/j.colsurfb.2025.115034_bib36","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1039\/D3CE00773A","article-title":"Cocrystallization of multi-kinase inhibitor pazopanib with fenamic acids: improving dissolution and inhibiting cell migration","volume":"25","author":"Rai","year":"2023","journal-title":"CrystEngComm"},{"key":"10.1016\/j.colsurfb.2025.115034_bib37","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ejps.2015.08.002","article-title":"Simultaneous improvement of solubility and permeability by fabricating binary glassy materials of talinolol with naringin: solid state characterization, in-vivo in-situ evaluation","volume":"78","author":"Teja","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.colsurfb.2025.115034_bib38","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejpb.2022.11.013","article-title":"Selection of bionic Co-former improves the dissolution of neohesperidin via Co-amorphous solid dispersion with naringin","volume":"181","author":"Li","year":"2022","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"5","key":"10.1016\/j.colsurfb.2025.115034_bib39","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1021\/mp2002973","article-title":"Coamorphous drug systems: enhanced physical stability and dissolution rate of indomethacin and naproxen","volume":"8","author":"L\u00f6bmann","year":"2011","journal-title":"Mol. Pharm."},{"issue":"8-10","key":"10.1016\/j.colsurfb.2025.115034_bib40","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1080\/05704928.2021.1946822","article-title":"FTIR spectroscopy in biomedical research: how to get the most out of its potential","volume":"56","author":"Magalh\u00e3es","year":"2021","journal-title":"Appl. Spectrosc. Rev."},{"issue":"54","key":"10.1016\/j.colsurfb.2025.115034_bib41","doi-asserted-by":"crossref","first-page":"39844","DOI":"10.1039\/D4RA07079H","article-title":"Production of pazopanib hydrochloride nanoparticles (anti-kidney cancer drug) using a supercritical gas antisolvent (GAS) method","volume":"14","author":"Bazaei","year":"2024","journal-title":"RSC Adv."},{"key":"10.1016\/j.colsurfb.2025.115034_bib42","article-title":"Exploring the utility of co-amorphous materials to concurrently improve the solubility and permeability of fexofenadine","volume":"72","author":"Uppala","year":"2022","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"1-2","key":"10.1016\/j.colsurfb.2025.115034_bib43","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ijpharm.2007.11.048","article-title":"Characterisation of solid dispersions of paracetamol and EUDRAGIT\u00ae e prepared by hot-melt extrusion using thermal, microthermal and spectroscopic analysis","volume":"354","author":"Qi","year":"2008","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.colsurfb.2025.115034_bib44","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1515\/geo-2020-0145","article-title":"The significance of scanning electron microscopy (SEM) analysis on the microstructure of improved clay: an overview","volume":"13","author":"Ural","year":"2021","journal-title":"Open Geosci."},{"issue":"2","key":"10.1016\/j.colsurfb.2025.115034_bib45","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/14786419.2019.1628752","article-title":"Synthesis and biophysical analysis of Naringin-Chitooligosaccharide complex","volume":"35","author":"Cao","year":"2021","journal-title":"Nat. Prod. Res."},{"key":"10.1016\/j.colsurfb.2025.115034_bib46","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10847-017-0704-x","article-title":"Experimental and computational studies of naringin\/cyclodextrin inclusion complexation","volume":"88","author":"Yan","year":"2017","journal-title":"J. Incl. Phenom. Macrocycl. Chem."},{"key":"10.1016\/j.colsurfb.2025.115034_bib47","series-title":"in Dosage Forms, Formulation Developments and Regulations","first-page":"395","article-title":"Preformulation considerations in pharmaceutical formulation process","author":"Sallam","year":"2024"},{"issue":"2","key":"10.1016\/j.colsurfb.2025.115034_bib48","doi-asserted-by":"crossref","first-page":"630","DOI":"10.3390\/pharmaceutics15020630","article-title":"Ball-Milling preparation of the Drug\u2013Drug solid form of Pioglitazone-Rosuvastatin at different molar ratios: characterization and intrinsic dissolution rates evaluation","volume":"15","author":"Mu\u00f1oz Tecocoatzi","year":"2023","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.colsurfb.2025.115034_bib49","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ijpharm.2017.08.078","article-title":"Importance of in vitro dissolution conditions for the in vivo predictability of an amorphous solid dispersion containing a pH-sensitive carrier","volume":"531","author":"Wendelboe","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.colsurfb.2025.115034_bib50","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejpb.2023.01.018","article-title":"Co-amorphous formulation of dipyridamole with p-hydroxybenzoic acid: underlying molecular mechanisms, physical stability, dissolution behavior and pharmacokinetic study","volume":"184","author":"Guo","year":"2023","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"6","key":"10.1016\/j.colsurfb.2025.115034_bib51","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1517\/17425247.2014.911728","article-title":"Refining stability and dissolution rate of amorphous drug formulations","volume":"11","author":"Grohganz","year":"2014","journal-title":"Expert Opin. Drug Deliv."},{"issue":"5","key":"10.1016\/j.colsurfb.2025.115034_bib52","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1021\/acs.cgd.0c00073","article-title":"Evidence for halogen bonding in amorphous solid dispersions","volume":"20","author":"Que","year":"2020","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.colsurfb.2025.115034_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116527","article-title":"A new framework for novel analogues of pazopanib as potent and selective human carbonic anhydrase inhibitors: design, repurposing rational, synthesis, crystallographic, in vivo and in vitro biological assessments","volume":"274","author":"Hefny","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.colsurfb.2025.115034_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.molliq.2025.127225","article-title":"Enhancing solubility, bioavailability and anti-cancer efficacy of aprepitant through a naringin-based co-amorphous system","volume":"425","author":"Pardhi","year":"2025","journal-title":"J. Mol. Liq."},{"issue":"5","key":"10.1016\/j.colsurfb.2025.115034_bib55","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.3390\/chemistry6050063","article-title":"An alternative method for synthesizing N, 2, 3-Trimethyl-2H-indazol-6-amine as a key component in the preparation of pazopanib","volume":"6","author":"Bui","year":"2024","journal-title":"Chemistry"},{"issue":"3","key":"10.1016\/j.colsurfb.2025.115034_bib56","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1021\/acs.molpharmaceut.8b01229","article-title":"Transformations between co-amorphous and co-crystal systems and their influence on the formation and physical stability of co-amorphous systems","volume":"16","author":"Wu","year":"2019","journal-title":"Mol. Pharm."},{"issue":"2","key":"10.1016\/j.colsurfb.2025.115034_bib57","first-page":"62","article-title":"Bioanalytical method development and validation of pazopanib hydrochloride by Uv-Visible spectrometry and Rp-Hplc in human plasma","volume":"12","author":"Gupta","year":"2021","journal-title":"J. Pharm. Negat. Results"},{"key":"10.1016\/j.colsurfb.2025.115034_bib58","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s13318-015-0252-y","article-title":"Metabolic behavior prediction of pazopanib by cytochrome P450 (CYP) 3A4 by molecular docking","volume":"41","author":"Liu","year":"2016","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.colsurfb.2025.115034_bib59","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1007\/s11095-008-9793-y","article-title":"Naringenin enhances the anti-tumor effect of doxorubicin through selectively inhibiting the activity of multidrug resistance-associated proteins but not P-glycoprotein","volume":"26","author":"Zhang","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.colsurfb.2025.115034_bib60","first-page":"1","article-title":"Enhanced oral bioavailability of pranlukast by preparing amorphous solid dispersion via hot-melt extrusion","author":"Ha","year":"2025","journal-title":"J. Pharm. Investig."},{"issue":"10","key":"10.1016\/j.colsurfb.2025.115034_bib61","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s12272-022-01407-0","article-title":"Enhanced bioavailability and hepatoprotective effect of silymarin by preparing silymarin-loaded solid dispersion formulation using freeze-drying method","volume":"45","author":"Lim","year":"2022","journal-title":"Arch. Pharmacal Res."},{"issue":"1","key":"10.1016\/j.colsurfb.2025.115034_bib62","first-page":"1","article-title":"Combinatorial nanocarrier based drug delivery approach for amalgamation of anti-tumor agents in breast cancer cells: an improved nanomedicine strategy","volume":"6","author":"Murugan","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.colsurfb.2025.115034_bib63","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ijbiomac.2014.08.012","article-title":"Therapeutic efficacy and toxicity of tamoxifen loaded PLA nanoparticles for breast cancer","volume":"72","author":"Pandey","year":"2015","journal-title":"Int. J. Biol. Macromol."},{"issue":"11","key":"10.1016\/j.colsurfb.2025.115034_bib64","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1080\/03639045.2018.1496445","article-title":"Augmented anticancer activity of naringenin-loaded TPGS polymeric nanosuspension for drug resistive MCF-7 human breast cancer cells","volume":"44","author":"Rajamani","year":"2018","journal-title":"Drug Dev. Ind. Pharm."}],"container-title":["Colloids and Surfaces B: Biointerfaces"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0927776525005417?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0927776525005417?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T18:33:14Z","timestamp":1772821994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0927776525005417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":64,"alternative-id":["S0927776525005417"],"URL":"https:\/\/doi.org\/10.1016\/j.colsurfb.2025.115034","relation":{},"ISSN":["0927-7765"],"issn-type":[{"value":"0927-7765","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhancing oral bioavailability of pazopanib via co-amorphous system: Formulation, characterization, pharmacokinetics and toxicity evaluation","name":"articletitle","label":"Article Title"},{"value":"Colloids and Surfaces B: Biointerfaces","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.colsurfb.2025.115034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115034"}}